Latest Headlines

  1. Predictive Oncology And Cvergenx Announce Partnership To Develop The First-Ever Genomics-Based Approach To Precision Radiation Therapy And Drug Discovery Using Artificial Intelligence 2/23/2023

    Predictive Oncology Inc. (NASDAQ: POAI) and Cvergenx, Inc. today announced an agreement to form a strategic partnership that has the potential to revolutionize the field of radiation oncology with the first-ever genomics-based artificial intelligence approach to personalized radiotherapy and drug discovery.

  2. Shuttle Pharmaceuticals Expands Laboratory Space To Advance Drug Development Pipeline And Diagnostic Capabilities 2/23/2023

    Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced it has entered an agreement to lease new laboratory and office space, commencing in June 2023, to complement the development of the Company's lead drug candidates and accelerate broader diagnostic capabilities on predictive biomarkers.

  3. Alnylam Announces U.S. Food And Drug Administration (FDA) Acceptance Of Supplemental New Drug Application For ONPATTRO (Patisiran) For The Treatment Of The Cardiomyopathy Of ATTR Amyloidosis 2/21/2023

    Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s supplemental New Drug Application (sNDA) for patisiran, an investigational RNAi therapeutic in development for the treatment of the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis.

  4. Predictive Oncology Launches ACE Program To Partner With Academic And Research Institutions To Advance Their Drug Discovery Initiatives 2/21/2023

    Predictive Oncology Inc. (NASDAQ: POAI) today announced the launch of ACE (Accelerating Compound Exploration), a program to advance the oncology drug development initiatives with academic and research institutions

  5. AbCheck Announces Collaboration To Apply Microfluidics Technology To The Discovery Of Antibodies Against Challenging Therapeutic Neurology Target 2/21/2023

    AbCheck s.r.o., a technology company delivering disruptive antibody discovery and development solutions for challenging targets, announced today that it has entered into a collaboration with a biotech company developing antibodies targeting peripheral neural response, funded by a top-tier European Venture Capital firm

  6. Biohaven's Taldefgrobep Alfa Receives FDA Fast Track Designation For Spinal Muscular Atrophy 2/21/2023

    Biohaven Ltd. (NYSE: BHVN; "Biohaven") announced today that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for taldefgrobep alfa, a novel anti-myostatin adnectin, for the treatment of spinal muscular atrophy (SMA)

  7. Teijin And Axcelead To Establish Drug Discovery Research JV 2/20/2023

    Teijin Limited and Axcelead, Inc. jointly announced today their basic agreement on a capital and business alliance to establish a joint venture company that will primarily utilize the drug discovery research capabilities of Teijin Pharma Limited, the Teijin Group's core healthcare company

  8. Using Light To Switch Drugs On And Off 2/20/2023

    Photopharmacology is a new field of medicine that is predicted to have a great future. It could help to treat diseases such as cancer even more effectively than before. Photopharmacological drugs are fitted with a molecular photoswitch. The substance is activated by a pulse of light, but only once it has reached the region of the body where it is meant to act. And after it has done its job, it can be switched off again by another pulse of light.

  9. Iveric Bio Announces FDA Accepts New Drug Application And Grants Priority Review For Avacincaptad Pegol For The Treatment Of Geographic Atrophy 2/16/2023

    IVERIC bio, Inc. today announced that the U.S. Food and Drug Administration (FDA) has completed its filing review and accepted the company’s New Drug Application (NDA) for avacincaptad pegol (ACP), a novel investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to Age-Related Macular Degeneration (AMD). 

  10. Cure Rare Disease Receives Muscular Dystrophy Association Grant 2/16/2023

    Cure Rare Disease, a clinical-stage nonprofit biotechnology company, has been awarded an advocacy collaboration grant from the Muscular Dystrophy Association (MDA) to support research on novel reimbursement strategies for drugs developed for ultra-rare diseases, a key challenge for rare disease patients, including muscular dystrophy patients